Skip to main content

Table 1 Demographic and clinical characteristics

From: The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients

Number of patients Total No hyponatremia episode ≥1 hyponatremia episode P value
N = 1758 n = 815 n = 943
Demographic characteristics
Sex, n (%)     <0.01
 Male 503 (29) 145 (18) 358 (38)  
 Female 1255 (71) 670 (82) 585 (62)
Age group collapsed, n (%)     0.06
 18–64 1108 (63) 533 (65) 575 (61)  
 ≥65 650 (37) 282 (35) 368 (39)
Mean age (SD) 60.2 (13) 59.6 (13) 60.6 (13) 0.11
Race, n (%)     0.09
 Asian 18 (1) 8 (1) 10 (1)  
 Black 340 (19) 179 (22) 161 (17)
 White 1393 (79) 627 (77) 766 (81)
Median household income, n (%)     0.16
 ≤$49,999 1030 (59) 480 (59) 550 (58)  
 $50,000–$69,999 460 (26) 197 (24) 263 (28)
 ≥$70,000 239 (14) 123 (15) 116 (12)
Diagnosis year, n (%)     0.02
 2002–2004 270 (15) 146 (18) 124 (13)  
 2005–2007 869 (49) 386 (47) 483 (51)
 2008–2010 619 (35) 283 (35) 336 (36)
Mean length of follow-up, y (SD) 3.1 (3) 3.3 (3) 3.0 (3) 0.03
Clinical characteristics at baseline
Cancer type, n (%)     
 Breast 839 (48) 533 (65) 306 (32) <0.01
 Colorectal 233 (13) 84 (10) 149 (16) <0.01
  Colon 146 (8) 50 (61) 96 (10) <0.01
  Rectal 87 (5) 34 (4) 53 (6) 0.16
 Lung 485 (28) 117 (14) 368 (39) <0.01
  Small cell 80 (5) 19 (2) 61 (7) <0.01
  Non-small cell 405 (23) 98 (12) 307 (33) <0.01
 Lymphoma 201 (11) 81 (10) 120 (13) 0.07
  Hodgkins 29 (2) 12 (2) 17 (2) 0.59
  Non-Hodgkins 172 (10) 69 (9) 103 (11) 0.08
Distant metastasis, n (%) 384 (22) 99 (12) 285 (30) <0.01
Any PS within 90 days of diagnosis, n (%) 864 (49) 384 (47) 480 (51) 0.11
 Grade 1: ECOG 0, 1; KPS 80–100a 747 (87) 350 (91) 397 (83) <0.01
 Grade 2: ECOG 2; KPS 60–70a 78 (9) 26 (7) 52 (11) 0.04
 Grade 3: ECOG 3, 4; KPS 10–50a 39 (5) 8 (2) 31 (7) <0.01
Clinical characteristics during follow-up
Distant metastasis, n (%) 513 (29) 120 (15) 393 (42) <0.01
PS, last observed documentation, n (%) 1249 (71) 553 (68) 696 (74) <0.01
 Grade 1: ECOG 0, 1; KPS 80–100a 990 (79) 499 (90) 491 (71) <0.01
 Grade 2: ECOG 2; KPS 60–70a 141 (11) 34 (6) 107 (15) <0.01
 Grade 3: ECOG 3, 4; KPS 10–50a 118 (9) 20 (4) 98 (14) <0.01
Hospice services, n (%) 129 (7) 21 (3) 108 (12) <0.01
First course surgical resection, n (%) 1029 (62) 563 (72) 466 (52) <0.01
Any chemo and hormonal therapies, n (%) 1410 (80) 595 (73) 815 (86) <0.01
 Alkylating agentsb 547 (39) 269 (45) 278 (34) <0.01
 Antimetabolitesb 427 (30) 113 (19) 314 (39) <0.01
 Antitumor antibioticsb 452 (32) 223 (38) 229 (28) <0.01
 Hormone therapyb 594 (42) 318 (53) 276 (34) <0.01
 Mitotic inhibitorsb 761 (54) 260 (44) 501 (62) <0.01
 Platinum agentsb 512 (36) 114 (19) 398 (49) <0.01
 Targeted therapiesb 375 (27) 124 (21) 251 (31) <0.01
Otherc 175 (10) 48 (6) 127 (13) <0.01
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, KPS Karnofsky PS, PS performance status, SD standard deviation, y year
  2. aPercent of patients with any PS
  3. bPercent of patients with any chemo or hormonal therapy
  4. cOther treatments including immunotherapies and topoisomerases